Webinar Abstract:

Lentiviral vectors (LVVs) remain central to genetic engineering strategies in CAR-T cell therapy. Since the first approvals of LVV-engineered autologous products, such as Kymriah^®, the field has steadily advanced toward in vivo gene-delivery approaches that enable direct T-cell modification in patients. This evolution increases the need for manufacturing platforms that are scalable, cost-efficient, and aligned with evolving regulatory expectations for systemic administration. 

In this webinar, we will examine the current landscape of LVV process development, highlighting the shift from traditional ex vivo applications to emerging in vivo modalities. We will also discuss how our company has developed a robust, industrialized downstream platform that supports ex vivo CAR-T manufacturing while delivering the quality, consistency, and process control required for in vivo therapeutic use. 

Our expert, Brian Tomkowicz, will guide you through key insights from this session, including: 

1. How LVV design and quality requirements differ between ex vivo and in vivo CAR-T applications
2. Scalable and cost-efficient approaches for industrialized LVV manufacturing
3. The impact of evolving regulatory and quality expectations on modern LVV platform development